ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-137

thanks for clarifying.

I, too, cant find the legal words. However my view is the ability for NNZ2591 to directly compete with Daybue (and hence Acadia) was removed with the below wording:

"Neuren has also granted to Acadia an exclusive worldwide licence to develop and commercialise NNZ2591 for Rett syndrome and Fragile X syndrome only. This enables coordinated global development, replacing the restrictions in the existing agreement on use by Neuren in those two indications."

I also recall a few brokers (at the time) upgraded their analysis based on this wording, agreeing that it de-risked NNZ competing with Acadia given Neuren will now receive the tiered royalties and funds associated with those two indications...regardless of what drug Acadia uses to treat the conditions.

IMO - and I havent seen anything to contradict my belief - the potential conflict between NNZ2591 and Daybue was always regarding Retts, given the previous commercial agreement...and never involved the other indications.